Enzo Biochem’s Clinical Labs Unit Enters into Co-Marketing Program with MMF Systems, Inc., for Web-Based Medical Records and Practice Management Software

Enzo Biochem, Inc., (NYSE: ENZ) announced today that Enzo Clinical Labs, Inc., its reference lab division serving physicians and medical facilities in the New York metropolitan area, has entered into a trial co-marketing services agreement with privately-owned MMF Systems, Inc. ("MMF”), of New York City, involving MMF’S state of the art medical records system.

Specifically, the agreement provides for the introduction to a targeted list of several thousand current and prospective physician clients by Enzo Clinical Labs and MMF. Enzo will co-market its diagnostic services capabilities along with MMF, the developer of web-based open source electronic medical record and practice management software. MMF is a leading provider of online information systems to the medical community. The initial trial period is for six months, after which the parties will determine whether to extend the joint marketing program.

"Electronic medical record keeping is a program whose time has come, and the opportunity for Enzo to offer our clients as well as other prospective customers MMF’s advanced system is expected to benefit our Lab’s overall efforts as we continue to enhance our extensive physician connectivity solutions,” said James Delaney, Chief Information Officer of Enzo Clinical Labs. "We look forward to working with MMF on this trial program with great enthusiasm.”

"MMF is very pleased to partner with Enzo Clinical Labs in this marketing effort of our web-based medical records system,” said Dr. Nathan Capoor, President and CEO of MMF. "Apart from its outstanding reputation, Enzo Clinical Labs enjoys a far reaching broad spectrum of physicians in New York, New Jersey and Pennsylvania for whom this program should be ideally suited, and it, in addition, will be able to reach thousands of other physicians in our proprietary database.”

About Enzo Biochem

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Sciences develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research, among others. Its catalog of over 40,000 products serve the molecular biology, drug discovery and pathology research markets worldwide. Enzo Clinical Labs provides laboratory services for a growing roster of physicians in the New York Metropolitan area, as well as parts of New Jersey and Pennsylvania. Its tests include, in addition to routine tests, capabilities for detecting molecular infection disease, molecular oncology, autoimmune disorders and genetics. Enzo Clinical Labs also provides clinical diagnostic services that allow Enzo to capitalize on its extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. It has focused its efforts on developing treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. In the course of the company’s research and development activities, Enzo has developed a substantial portfolio of intellectual property assets, with 249 issued patents worldwide and over 200 pending patent applications.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.